Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 344 Results
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
January 10, 2023
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
January 5, 2023
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
November 14, 2022
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
November 9, 2022
Palatin Announces $10 Million Registered Direct Offering
October 31, 2022
Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
October 24, 2022
First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial
October 20, 2022
Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
October 17, 2022
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
October 13, 2022
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
September 29, 2022
Page 10 of 35